High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma

T. E. Tanimoto, E. Kusumi, T. Hamaki, K. Yuji, J. Ueyama, S. Miyakoshi, S. Morinaga, M. Kami, Y. Kanda, T. Ando, S. Yoshihara, S. Masuo, S. W. Kim, K. Nakai, K. Tobinai, Ryuji Tanosaki, S. Mineishi, Y. Takaue, Y. Muto

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The possible advantage of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a graft-versus-lymphoma effect. We explored the feasibility and efficacy of allo-HSCT with reduced-intensity (RI) regimens in advanced malignant lymphoma (ML). A total of 20 patients with indolent (n = 9) or aggressive lymphoma (n = 11) received allo-HSCT with an RI regimen (RIST). The preparative regimen consisted of a combination of purine analog and alkylating agent with or without antithymocyte globulin. A total of 11 patients had chemorefractory disease, seven had chemosensitive relapsed disease and two had residual disease. All of the patients received G-CSF-mobilized blood stem cells from HLA-matched siblings. Of the 20 patients, 19 achieved engraftment with acceptable regimen-related toxicities. Seven patients developed grade II-IV acute GVHD and 15 developed chronic GVHD. Of the 15 patients with evaluable disease, 12 achieved a complete response. One died of invasive fusariosis, four subsequently died of GVHD complicated with fungal infection and one died of progressive disease. With a median follow-up of 358 days, the Kaplan-Meier estimates for 1-year overall and progression-free survival were both 70%. The high response rate with low relapse observed in this study suggests that RIST may be an effective alternative curative treatment for patients with advanced ML.

Original languageEnglish
Pages (from-to)131-137
Number of pages7
JournalBone Marrow Transplantation
Volume32
Issue number2
DOIs
Publication statusPublished - 2003 Jul
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Lymphoma
Fusariosis
Antilymphocyte Serum
Mycoses
Alkylating Agents
Kaplan-Meier Estimate
Granulocyte Colony-Stimulating Factor
Conditioning (Psychology)
Disease-Free Survival
Siblings
Blood Cells
Stem Cells
Transplants
Recurrence

Keywords

  • Allogeneic transplantation
  • Malignant lymphoma
  • Reduced-intensity regimen

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. / Tanimoto, T. E.; Kusumi, E.; Hamaki, T.; Yuji, K.; Ueyama, J.; Miyakoshi, S.; Morinaga, S.; Kami, M.; Kanda, Y.; Ando, T.; Yoshihara, S.; Masuo, S.; Kim, S. W.; Nakai, K.; Tobinai, K.; Tanosaki, Ryuji; Mineishi, S.; Takaue, Y.; Muto, Y.

In: Bone Marrow Transplantation, Vol. 32, No. 2, 07.2003, p. 131-137.

Research output: Contribution to journalArticle

Tanimoto, TE, Kusumi, E, Hamaki, T, Yuji, K, Ueyama, J, Miyakoshi, S, Morinaga, S, Kami, M, Kanda, Y, Ando, T, Yoshihara, S, Masuo, S, Kim, SW, Nakai, K, Tobinai, K, Tanosaki, R, Mineishi, S, Takaue, Y & Muto, Y 2003, 'High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma', Bone Marrow Transplantation, vol. 32, no. 2, pp. 131-137. https://doi.org/10.1038/sj.bmt.1704118
Tanimoto, T. E. ; Kusumi, E. ; Hamaki, T. ; Yuji, K. ; Ueyama, J. ; Miyakoshi, S. ; Morinaga, S. ; Kami, M. ; Kanda, Y. ; Ando, T. ; Yoshihara, S. ; Masuo, S. ; Kim, S. W. ; Nakai, K. ; Tobinai, K. ; Tanosaki, Ryuji ; Mineishi, S. ; Takaue, Y. ; Muto, Y. / High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. In: Bone Marrow Transplantation. 2003 ; Vol. 32, No. 2. pp. 131-137.
@article{4021ac7eeaf64a89b97d0a7b4fa17fd2,
title = "High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma",
abstract = "The possible advantage of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a graft-versus-lymphoma effect. We explored the feasibility and efficacy of allo-HSCT with reduced-intensity (RI) regimens in advanced malignant lymphoma (ML). A total of 20 patients with indolent (n = 9) or aggressive lymphoma (n = 11) received allo-HSCT with an RI regimen (RIST). The preparative regimen consisted of a combination of purine analog and alkylating agent with or without antithymocyte globulin. A total of 11 patients had chemorefractory disease, seven had chemosensitive relapsed disease and two had residual disease. All of the patients received G-CSF-mobilized blood stem cells from HLA-matched siblings. Of the 20 patients, 19 achieved engraftment with acceptable regimen-related toxicities. Seven patients developed grade II-IV acute GVHD and 15 developed chronic GVHD. Of the 15 patients with evaluable disease, 12 achieved a complete response. One died of invasive fusariosis, four subsequently died of GVHD complicated with fungal infection and one died of progressive disease. With a median follow-up of 358 days, the Kaplan-Meier estimates for 1-year overall and progression-free survival were both 70{\%}. The high response rate with low relapse observed in this study suggests that RIST may be an effective alternative curative treatment for patients with advanced ML.",
keywords = "Allogeneic transplantation, Malignant lymphoma, Reduced-intensity regimen",
author = "Tanimoto, {T. E.} and E. Kusumi and T. Hamaki and K. Yuji and J. Ueyama and S. Miyakoshi and S. Morinaga and M. Kami and Y. Kanda and T. Ando and S. Yoshihara and S. Masuo and Kim, {S. W.} and K. Nakai and K. Tobinai and Ryuji Tanosaki and S. Mineishi and Y. Takaue and Y. Muto",
year = "2003",
month = "7",
doi = "10.1038/sj.bmt.1704118",
language = "English",
volume = "32",
pages = "131--137",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma

AU - Tanimoto, T. E.

AU - Kusumi, E.

AU - Hamaki, T.

AU - Yuji, K.

AU - Ueyama, J.

AU - Miyakoshi, S.

AU - Morinaga, S.

AU - Kami, M.

AU - Kanda, Y.

AU - Ando, T.

AU - Yoshihara, S.

AU - Masuo, S.

AU - Kim, S. W.

AU - Nakai, K.

AU - Tobinai, K.

AU - Tanosaki, Ryuji

AU - Mineishi, S.

AU - Takaue, Y.

AU - Muto, Y.

PY - 2003/7

Y1 - 2003/7

N2 - The possible advantage of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a graft-versus-lymphoma effect. We explored the feasibility and efficacy of allo-HSCT with reduced-intensity (RI) regimens in advanced malignant lymphoma (ML). A total of 20 patients with indolent (n = 9) or aggressive lymphoma (n = 11) received allo-HSCT with an RI regimen (RIST). The preparative regimen consisted of a combination of purine analog and alkylating agent with or without antithymocyte globulin. A total of 11 patients had chemorefractory disease, seven had chemosensitive relapsed disease and two had residual disease. All of the patients received G-CSF-mobilized blood stem cells from HLA-matched siblings. Of the 20 patients, 19 achieved engraftment with acceptable regimen-related toxicities. Seven patients developed grade II-IV acute GVHD and 15 developed chronic GVHD. Of the 15 patients with evaluable disease, 12 achieved a complete response. One died of invasive fusariosis, four subsequently died of GVHD complicated with fungal infection and one died of progressive disease. With a median follow-up of 358 days, the Kaplan-Meier estimates for 1-year overall and progression-free survival were both 70%. The high response rate with low relapse observed in this study suggests that RIST may be an effective alternative curative treatment for patients with advanced ML.

AB - The possible advantage of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a graft-versus-lymphoma effect. We explored the feasibility and efficacy of allo-HSCT with reduced-intensity (RI) regimens in advanced malignant lymphoma (ML). A total of 20 patients with indolent (n = 9) or aggressive lymphoma (n = 11) received allo-HSCT with an RI regimen (RIST). The preparative regimen consisted of a combination of purine analog and alkylating agent with or without antithymocyte globulin. A total of 11 patients had chemorefractory disease, seven had chemosensitive relapsed disease and two had residual disease. All of the patients received G-CSF-mobilized blood stem cells from HLA-matched siblings. Of the 20 patients, 19 achieved engraftment with acceptable regimen-related toxicities. Seven patients developed grade II-IV acute GVHD and 15 developed chronic GVHD. Of the 15 patients with evaluable disease, 12 achieved a complete response. One died of invasive fusariosis, four subsequently died of GVHD complicated with fungal infection and one died of progressive disease. With a median follow-up of 358 days, the Kaplan-Meier estimates for 1-year overall and progression-free survival were both 70%. The high response rate with low relapse observed in this study suggests that RIST may be an effective alternative curative treatment for patients with advanced ML.

KW - Allogeneic transplantation

KW - Malignant lymphoma

KW - Reduced-intensity regimen

UR - http://www.scopus.com/inward/record.url?scp=10744232971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744232971&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704118

DO - 10.1038/sj.bmt.1704118

M3 - Article

VL - 32

SP - 131

EP - 137

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -